There are 2789 resources available
1171MO - PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
Presenter: Nicolas Girard
Session: Mini oral session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA61 - Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study
Presenter: Luis Paz-Ares
Session: Mini oral session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1172MO - Durvalumab consolidation in patients with stage III non-resecable NSCLC with driver genomic alterations
Presenter: Mariona Riudavets Melia
Session: Mini oral session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
654MO - A phase II prospective trial of frontline cabozantinib in metastatic collecting ducts renal cell carcinoma: The BONSAI trial (Meeturo 2)
Presenter: Giuseppe Procopio
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
655MO - A prospective phase II trial of cabazitaxel in male patients with chemotherapy pre-treated metastatic germ-cell tumors: The CABA-GCT study
Presenter: Giulia Baciarello
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
656MO - Phase II study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, plus cabozantinib for treatment of advanced clear cell renal cell carcinoma (ccRCC)
Presenter: David McDermott
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
657MO - Antibiotic (ATB) therapy and outcome from nivolumab (N) in metastatic renal cell carcinoma (mRCC) patients (pts): Results of the GETUG-AFU 26 NIVOREN multicentric phase II study
Presenter: Lisa Derosa
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
658MO - Cisplatin (cis)-related immunomodulation and efficacy with atezolizumab (atezo) + cis- vs carboplatin (carbo)-based chemotherapy (chemo) in metastatic urothelial cancer (mUC)
Presenter: Matthew Galsky
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
659MO - Avelumab (A) as the basis of neoadjuvant chemotherapy (NAC) regimen in platinum eligible and ineligible patients (pts) with non-metastatic muscle invasive bladder cancer (NM-MIBC)
Presenter: Nieves Martinez Chanza
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA31 - High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advanced urothelial cancer (NABUCCO cohort 2)
Presenter: Jeroen Van Dorp
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast